Your Top 50 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
Amanda K. Psyrri, Jérôme Fayette, Kevin Joseph Harrington, Maura L. Gillison, M-J. Ahn, Shunji Takahashi and 22 more
- Rank
- 33 of 3,616
- Percentile
- top 1%
- Where
- Annals of Oncology, 2022
- Citations
- 153
From the 2022 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.